By Hendra Lukman 
People with advanced lung or skin cancer who received a COVID-19 mRNA vaccine within 100 days of beginning immunotherapy lived considerably longer than those who did not, according to groundbreaking new research presented at the 2025 European Society for Medical Oncology (ESMO) Congress in Berlin. Scientists from the University of Florida (UF) and the University of Texas MD Anderson Cancer Center are hailing this discovery as a significant milestone in the decade-long pursuit of mRNA-based therapies that harness the body’s own immune system to combat cancer. This preliminary analysis, examining the medical records of over 1,000 patients, suggests a profound potential to enhance the efficacy of existing immunotherapies and pave the way for universal cancer vaccines.
A Serendipitous Discovery with Revolutionary Potential
The findings stem from a confluence of research efforts, including years of work by Dr. Elias Sayour, M.D., Ph.D., a UF Health pediatric oncologist and a leading investigator in mRNA cancer vaccine development. His laboratory has been dedicated to combining lipid nanoparticles with mRNA, the genetic messenger molecule that carries instructions for protein synthesis within cells. This foundational research has been exploring the potential of mRNA to instruct the immune system to recognize and attack cancer cells.
A pivotal moment in this research occurred in July, when Dr. Sayour’s team made an unexpected discovery: it was not necessary to target specific tumor proteins to elicit a robust immune response against cancer. Instead, they found that stimulating the immune system to react as if it were combating a viral infection could be equally, if not more, effective. This "nonspecific" mRNA vaccine approach, when paired with immune checkpoint inhibitors—a class of drugs that essentially "release the brakes" on the immune system, allowing it to more effectively identify and destroy cancer cells—demonstrated a powerful antitumor effect in preclinical mouse models. Importantly, this experimental vaccine was not tailored to a specific virus or cancer type, but rather utilized similar technological principles to those employed in the highly successful COVID-19 mRNA vaccines.
This breakthrough inspired Dr. Adam Grippin, M.D., Ph.D., a former UF researcher now at MD Anderson, to pose a critical question: could the readily available COVID-19 mRNA vaccine itself possess an immune-boosting effect that could benefit cancer patients undergoing immunotherapy? This question formed the basis of the retrospective study presented at ESMO.
Detailed Analysis of Patient Data Reveals Significant Survival Gains
The research team meticulously analyzed the medical records of patients diagnosed with Stage 3 and 4 non-small cell lung cancer and metastatic melanoma who received treatment at MD Anderson Cancer Center between 2019 and 2023. The study specifically focused on patients who received a COVID-19 mRNA vaccine within a 100-day window before or after initiating immunotherapy. These individuals were then compared to similar patient cohorts who underwent immunotherapy but did not receive a COVID-19 vaccine.
The results were striking. For advanced lung cancer patients, the study identified 180 individuals who received a COVID vaccine within the specified timeframe, alongside 704 control patients. The group that received the COVID vaccine experienced a near doubling of their median survival, increasing from 20.6 months to an impressive 37.3 months. This represents a substantial improvement in longevity for a patient population with a grim prognosis.
A similar, significant benefit was observed in patients with metastatic melanoma. Of the 210 patients analyzed, 43 had received a COVID vaccine within 100 days of starting immunotherapy, while 167 did not. In this cohort, median survival increased from 26.7 months to a range of 30 to 40 months. The data collection was ongoing at the time of the presentation, meaning the ultimate survival benefit could be even more pronounced as more patients’ outcomes are fully documented.
Crucially, the study found no comparable increases in longevity for patients who received non-mRNA vaccines, such as those for pneumonia or influenza. This suggests that the specific mechanism of mRNA technology is central to the observed survival benefit.
Understanding the Immunological Mechanism
The researchers hypothesize that the mRNA COVID-19 vaccine acts as a potent immunostimulant, effectively "flaring" the immune system. According to Dr. Sayour, "One of the mechanisms for how this works is when you give an mRNA vaccine, that acts as a flare that starts moving all of these immune cells from bad areas like the tumor to good areas like the lymph nodes." This redirection and activation of immune cells are believed to enhance their ability to recognize and attack cancer cells, particularly in conjunction with immunotherapy.
To further support their findings, UF researchers conducted experiments using mouse models. In these models, they paired immunotherapy drugs with an mRNA vaccine specifically designed to target the COVID spike protein. These experiments successfully demonstrated the ability to transform tumors that were previously unresponsive to immunotherapy into responsive ones, thereby thwarting tumor growth. This provides crucial preclinical validation for the proposed mechanism of action.
Implications for Future Cancer Treatment and Universal Vaccines
The implications of this research are far-reaching, potentially revolutionizing the landscape of oncologic care. Dr. Elias Sayour expressed immense optimism, stating, "The implications are extraordinary — this could revolutionize the entire field of oncologic care. We could design an even better nonspecific vaccine to mobilize and reset the immune response, in a way that could essentially be a universal, off-the-shelf cancer vaccine for all cancer patients."
The development of a universal, off-the-shelf cancer vaccine has been a long-sought goal in oncology. Such a vaccine would eliminate the need for personalized tumor sequencing and the complex manufacturing processes associated with many current cancer immunotherapies. This could make advanced cancer treatments more accessible and affordable globally.
Dr. Jeff Coller, Ph.D., a distinguished mRNA expert at Johns Hopkins University, underscored the broader significance of these findings, noting that they exemplify the ongoing, unexpected benefits of initiatives like Operation Warp Speed, the U.S. government’s rapid COVID-19 vaccine development program. "The results from this study demonstrate how powerful mRNA medicines truly are and that they are revolutionizing our treatment of cancer," Dr. Coller remarked.
A Call for Further Validation and Next Steps
While the preliminary results are exceptionally promising, researchers emphasize the need for rigorous validation through randomized clinical trials. "Although these results are from an observational study and require confirmation through a randomized clinical trial," the researchers stated, "the potential importance cannot be overstated."
Dr. Duane Mitchell, M.D., Ph.D., Dr. Grippin’s doctoral mentor and director of the UF Clinical and Translational Science Institute, echoed this sentiment, describing the discovery as "pivotal for the future of cancer treatment." He added, "Although not yet proven to be causal, this is the type of treatment benefit that we strive for and hope to see with therapeutic interventions — but rarely do. I think the urgency and importance of doing the confirmatory work can’t be overstated."
The next critical step is the launch of a large-scale clinical trial, which will be spearheaded by the UF-led OneFlorida+ Clinical Research Network. This consortium comprises hospitals, health centers, and clinics across multiple states, providing a robust infrastructure for conducting such pivotal studies. "One of our key motivations at OneFlorida is to move discoveries from academic settings out into the real world and the places where patients get care," said Betsy Shenkman, Ph.D., who leads the consortium.
If confirmed through randomized trials, these findings could unlock numerous possibilities for enhancing existing therapies and developing novel treatments. The potential for even incremental improvements—even a 5% or 10% increase in survival—could translate into invaluable extra time for patients battling advanced cancers, especially if a universal vaccine can be leveraged across a wide spectrum of cancer types and patient populations.
Contextualizing Immunotherapy and the Role of mRNA
The study’s findings are particularly significant given the limitations of current immunotherapy approaches for advanced cancers. In lung and skin cancers, immunotherapy drugs are designed to empower the immune system to recognize and attack malignant cells. However, in advanced stages of these diseases, a substantial proportion of patients do not respond well to these treatments, often after exhausting other conventional options like radiation therapy, surgery, and chemotherapy. The ability of a COVID-19 mRNA vaccine to enhance response rates in these recalcitrant cases holds immense promise.
The development of mRNA vaccine technology has been a rapid and transformative process, accelerated by the global urgency of the COVID-19 pandemic. The success of the Pfizer-BioNTech and Moderna COVID-19 vaccines in preventing severe illness and death demonstrated the power and versatility of mRNA as a platform for vaccine development. This research builds directly on that momentum, exploring its therapeutic potential beyond infectious diseases and into the complex realm of cancer.
Funding and Intellectual Property
This pioneering research was supported by funding from the National Cancer Institute and various philanthropic foundations, highlighting a collaborative effort to advance cancer treatment. It is also noteworthy that Dr. Sayour, Dr. Grippin, and Dr. Mitchell hold patents related to UF-developed mRNA vaccines. These patents have been licensed by iOncologi Inc., a biotechnology company that emerged from UF, and in which Dr. Mitchell has a vested interest. This underscores the translational aspect of the research, aiming to bring these scientific breakthroughs to patients.
In conclusion, the preliminary findings suggesting that COVID-19 mRNA vaccines can significantly extend survival for advanced cancer patients on immunotherapy represent a beacon of hope. While further rigorous clinical trials are imperative, this research offers a compelling glimpse into a future where mRNA technology could play a central role in transforming cancer care, potentially leading to more effective, accessible, and universal cancer vaccines.
